Protocol Ledger

NCT05605093 · Phase III · TERMINATED

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Interventional Phase III clinical trial protocol NCT05605093 sponsored by University of Minnesota in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-23 Enrollment: 602 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05605093
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)602 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05605093
Protocol FieldVerified Registry Value
NCT IdentifierNCT05605093
Consolidated Lead SponsorUniversity of Minnesota
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment602 participants (ACTUAL)
Registered Start Date2022-12-23
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI